Top

Published in:

01-05-2020 | Glioma | Clinical Study

The influence of race and socioeconomic status on therapeutic clinical trial screening and enrollment

Authors: Ramin A. Morshed, Sheantel J. Reihl, Annette M. Molinaro, Sofia Kakaizada, Jacob S. Young, Jessica D. Schulte, Nicholas Butowski, Jennie Taylor, Nancy Ann Bush, Manish K. Aghi, Mitchel S. Berger, Susan Chang, Jennifer Clarke, Shawn L. Hervey-Jumper

Published in: Journal of Neuro-Oncology | Issue 1/2020

Abstract

Purpose

Under-enrollment in clinical trials significantly limits valid analyses of clinical interventions and generalizability of findings. Often it results in premature study termination, with estimates of 22% to 50% of clinical trials terminated due to poor accrual. Currently, there are limited reports addressing the influence of race/ethnicity and socioeconomic status on clinical trial enrollment in adult glioma patients. The goal of this study was to test the hypothesis that race and socioeconomic status negatively impact therapeutic clinical trial enrollment.

Methods

988 adult patients were identified from the UCSF Tumor Board Registry and analyzed to determine the rate of therapeutic clinical trial screening and study enrollment.

Results

At initial diagnosis, 43.6% and 17.5% of glioma patients were screened and enrolled in a therapeutic clinical trial, respectively. At recurrence, 49.8% and 26.3% of patients were screened and enrolled in a clinical trial, respectively. Thirty-three percent of the study population belonged to a NIH-designated underrepresented minority group; Asian/Pacific-Islander comprised 19.6% of the overall cohort. On univariate analysis, only in-state location, distance to the hospital, and WHO grade were associated with enrollment at initial diagnosis and recurrence. Minority status, insurance type, median household income, and percent below poverty were not associated with clinical trial enrollment.

Conclusion

Minority and socioeconomic status did not impact adult glioma clinical trial enrollment. Proximity to the tertiary care cancer center may be an important consideration for minority patients. Patient screening should be carefully considered in order to avoid bias based on minority and socioeconomic status.

Available only for authorised users

Hamel LM, Penner LA, Albrecht TL et al (2016) Barriers to clinical trial enrollment in racial and ethnic minority patients with cancer. Cancer Control 23:327–337. https://doi.org/10.1177/107327481602300404CrossRefPubMedPubMedCentral

Moorcraft SY, Marriott C, Peckitt C et al (2016) Patients’ willingness to participate in clinical trials and their views on aspects of cancer research: results of a prospective patient survey. Trials 17:17. https://doi.org/10.1186/s13063-015-1105-3CrossRefPubMedPubMedCentral

NIH (2001) Guidelines on the inclusion of women and minorities as subjects in clinical research. National Institue of Health, Bethesda

Freedman LS, Simon R, Foulkes MA et al (1995) Inclusion of women and minorities in clinical trials and the NIH Revitalization Act of 1993–the perspective of NIH clinical trialists. Control Clin Trials 16(277–279):293–309

Ostrom QT, Gittleman H, Liao P et al (2017) CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014. Neuro Oncol 19:v1–v88CrossRef

Chang SM, Barker FG 2nd, Schmidt MH et al (2002) Clinical trial participation among patients enrolled in the Glioma Outcomes Project. Cancer 94:2681–2687CrossRef

Field KM, Drummond KJ, Yilmaz M et al (2013) Clinical trial participation and outcome for patients with glioblastoma: Multivariate analysis from a comprehensive dataset. J Clin Neurosci 20:783–789. https://doi.org/10.1016/j.jocn.2012.09.013CrossRefPubMed

Kwiatkowski K, Coe K, Bailar JC, Swanson GM (2013) Inclusion of minorities and women in cancer clinical trials, a decade later: Have we improved? Cancer 119:2956–2963. https://doi.org/10.1002/cncr.28168CrossRefPubMed

Cheng SK, Dietrich MS, Dilts DM (2010) A sense of urgency: evaluating the link between clinical trial development time and the accrual performance of cancer therapy evaluation program (NCI-CTEP) sponsored studies. Clin Cancer Res 16:5557–5563. https://doi.org/10.1158/1078-0432.CCR-10-0133CrossRefPubMedPubMedCentral

10.

Korn EL, Freidlin B, Mooney M, Abrams JS (2010) Accrual experience of National Cancer Institute Cooperative Group phase III trials activated from 2000 to 2007. J Clin Oncol 28:5197–5201. https://doi.org/10.1200/JCO.2010.31.5382CrossRefPubMedPubMedCentral

11.

Massett HA, Mishkin G, Rubinstein L et al (2016) Challenges facing early phase trials sponsored by the National Cancer Institute: an analysis of corrective action plans to improve accrual. Clin Cancer Res 22:5408–5416. https://doi.org/10.1158/1078-0432.CCR-16-0338CrossRefPubMedPubMedCentral

12.

Tang C, Sherman SI, Price M et al (2017) Clinical trial characteristics and barriers to participant accrual: the MD Anderson cancer center experience over 30 years, a historical foundation for trial improvement. Clin Cancer Res 23:1414–1421. https://doi.org/10.1158/1078-0432.CCR-16-2439CrossRefPubMedPubMedCentral

13.

Ammanuel SG, Edwards CS, Alhadi R, Hervey-Jumper SL (2019) Readability of online neuro-oncology-related patient education materials from tertiary-care academic centers. World Neurosurg S1878–8750(19):32949–32953. https://doi.org/10.1016/j.wneu.2019.11.109CrossRef

14.

Chandra A, Rick JW, Dalle Ore C et al (2018) Disparities in health care determine prognosis in newly diagnosed glioblastoma. Neurosurg Focus 44:E16. https://doi.org/10.3171/2018.3.FOCUS1852CrossRefPubMedPubMedCentral

15.

Howerton MW, Gibbons MC, Baffi CR et al (2007) Provider roles in the recruitment of underrepresented populations to cancer clinical trials. Cancer 109:465–476. https://doi.org/10.1002/cncr.22436CrossRefPubMed

16.

Simon MS, Du W, Flaherty L et al (2004) Factors associated with breast cancer clinical trials participation and enrollment at a large academic medical center. J Clin Oncol 22:2046–2052. https://doi.org/10.1200/JCO.2004.03.005CrossRefPubMed

17.

Sabin JA, Rivara FP, Greenwald AG (2008) Physician implicit attitudes and stereotypes about race and quality of medical care. Med Care 46:678–685. https://doi.org/10.1097/MLR.0b013e3181653d58CrossRefPubMed

18.

Shavers VL, Lynch CF, Burmeister LF (2002) Racial differences in factors that influence the willingness to participate in medical research studies. Ann Epidemiol 12:248–256. https://doi.org/10.1016/S1047-2797(01)00265-4CrossRefPubMed

19.

Lewis JH, Kilgore ML, Goldman DP et al (2003) Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 21:1383–1389. https://doi.org/10.1200/JCO.2003.08.010CrossRefPubMed

20.

Murthy VH, Krumholz HM, Gross CP (2004) Participation in cancer clinical trials: race-, sex-, and age-based disparities. J Am Med Assoc 291:2720–2726. https://doi.org/10.1001/jama.291.22.2720CrossRef

21.

Tejeda HA, Green SB, Trimble EL et al (1996) Representation of African-Americans, Hispanics, and whites in National Cancer Institute cancer treatment trials. J Natl Cancer Inst 88:812–816. https://doi.org/10.1017/CBO9781107415324.004CrossRefPubMed

22.

Bhargava A, Du XL (2009) Racial and socioeconomic disparities in adjuvant chemotherapy for older women with lymph node-positive, operable breast cancer. Cancer 115:2999–3009. https://doi.org/10.1002/cncr.24363CrossRefPubMedPubMedCentral

23.

Schwartz K, Powell IJ, Underwood W et al (2009) Interplay of race, socioeconomic status, and treatment on survival of patients with prostate cancer. Urology 74:1296–1302. https://doi.org/10.1016/j.urology.2009.02.058CrossRefPubMedPubMedCentral

24.

Jimenez R, Zhang B, Joffe S et al (2013) Clinical trial participation among ethnic/racial minority and majority patients with advanced cancer: what factors most influence enrollment? J Palliat Med 16:256–262. https://doi.org/10.1089/jpm.2012.0413CrossRefPubMedPubMedCentral

25.

U.S. Census Bureau, Current Population Survey, 1968 to 2018 Annual Social and Economic Supplements. https://www.census.gov/content/dam/Census/library/visualizations/2018/demo/p60-263/figure1.pdf. Accessed 4 Apr 2020

Title: The influence of race and socioeconomic status on therapeutic clinical trial screening and enrollment
Authors: Ramin A. Morshed
Sheantel J. Reihl
Annette M. Molinaro
Sofia Kakaizada
Jacob S. Young
Jessica D. Schulte
Nicholas Butowski
Jennie Taylor
Nancy Ann Bush
Manish K. Aghi
Mitchel S. Berger
Susan Chang
Jennifer Clarke
Shawn L. Hervey-Jumper
Publication date: 01-05-2020
Publisher: Springer US
Keywords: Glioma
Glioma
Glioma
Published in: Journal of Neuro-Oncology / Issue 1/2020
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-020-03503-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The influence of race and socioeconomic status on therapeutic clinical trial screening and enrollment

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2020

Role of VHL-JAK-STAT signaling pathway in central nervous system hemangioblastoma associated with von Hippel-Lindau disease

Neurological outcome and memory performance in patients with 10 or more brain metastases treated with frameless linear accelerator (LINAC)-based stereotactic radiosurgery

Brain metastases resection cavity radio—surgery based on T2-weighted MRI: technique assessment

Neurocognitive functioning and health-related quality of life in adult medulloblastoma patients: long-term outcomes of the NOA-07 study

Symptomatic peritumoral edema is associated with surgical outcome: a consecutive series of 72 supratentorial meningioma patients ≥ 80 years of age

Chemoradiation in elderly patients with glioblastoma from the multi-institutional GBM-molRPA cohort: is short-course radiotherapy enough or is it a matter of selection?